Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 15;13(2):367.
doi: 10.3390/biom13020367.

Complement as a Biomarker for Systemic Lupus Erythematosus

Masahiro Ayano  1   2 , Takahiko Horiuchi  3
Affiliations
Review

Complement as a Biomarker for Systemic Lupus Erythematosus

Masahiro Ayano et al. Biomolecules. .

Abstract

Systemic lupus erythematosus (SLE) is a disease of immune complex deposition; therefore, complement plays a vital role in the pathogenesis of SLE. In general, complement levels in blood and complement deposition in histological tests are used for the management of SLE. Thus, the evaluation of complement status can be useful in the diagnosis of SLE, assessment of disease activity, and prediction of treatment response and prognosis. In addition, novel complement biomarkers, such as split products and cell-bound complement activation products, are considered to be more sensitive than traditional complement markers, such as serum C3 and C4 levels and total complement activity (CH50), which become more widely used. In this review, we report the complement testing in the management of SLE over the last decade and summarize their utility.

Keywords: cell-bound complement activation product; complement; lupus nephritis; serological activity; split product; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The complement cascade.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fanouriakis A., Tziolos N., Bertsias G., Boumpas D.T. Update in the Diagnosis and Management of Systemic Lupus Erythematosus. Ann. Rheum. Dis. 2021;80:14–25. doi: 10.1136/annrheumdis-2020-218272. - DOI - PubMed
    1. Pan L., Lu M.P., Wang J.H., Xu M., Yang S.R. Immunological Pathogenesis and Treatment of Systemic Lupus Erythematosus. World J. Pediatr. 2020;16:19–30. doi: 10.1007/s12519-019-00229-3. - DOI - PMC - PubMed
    1. Dörner T., Furie R. Novel Paradigms in Systemic Lupus Erythematosus. Lancet. 2019;393:2344–2358. doi: 10.1016/S0140-6736(19)30546-X. - DOI - PubMed
    1. van Vollenhoven R.F., Mosca M., Bertsias G., Isenberg D., Kuhn A., Lerstrøm K., Aringer M., Bootsma H., Boumpas D., Bruce I.N., et al. Treat-to-Target in Systemic Lupus Erythematosus: Recommendations from an International Task Force. Ann. Rheum. Dis. 2014;73:958–967. doi: 10.1136/annrheumdis-2013-205139. - DOI - PubMed
    1. Capecchi R., Puxeddu I., Pratesi F., Migliorini P. New Biomarkers in SLE: From Bench to Bedside. Rheumatology. 2020;59:V12–V18. doi: 10.1093/rheumatology/keaa484. - DOI - PMC - PubMed